These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 21849647)

  • 1. Interferon β-1b-neutralizing antibodies 5 years after clinically isolated syndrome.
    Hartung HP; Freedman MS; Polman CH; Edan G; Kappos L; Miller DH; Montalbán X; Barkhof F; Petkau J; White R; Sahajpal V; Knappertz V; Beckmann K; Lanius V; Sandbrink R; Pohl C;
    Neurology; 2011 Aug; 77(9):835-43. PubMed ID: 21849647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial.
    Goodin DS; Hartung HP; O'Connor P; Filippi M; Arnason B; Comi G; Cook S; Jeffery D; Kappos L; Bogumil T; Knappertz V; Sandbrink R; Beckmann K; White R; Petkau J; Pohl C;
    Mult Scler; 2012 Feb; 18(2):181-95. PubMed ID: 21952094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistency of neutralizing antibodies depends on titer and interferon-beta preparation.
    Hegen H; Schleiser M; Gneiss C; Di Pauli F; Ehling R; Kuenz B; Lutterotti A; Berger T; Deisenhammer F
    Mult Scler; 2012 May; 18(5):610-5. PubMed ID: 22013146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study.
    Kappos L; Clanet M; Sandberg-Wollheim M; Radue EW; Hartung HP; Hohlfeld R; Xu J; Bennett D; Sandrock A; Goelz S;
    Neurology; 2005 Jul; 65(1):40-7. PubMed ID: 16009883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of interferon beta neutralizing antibodies in multiple sclerosis: improvement of clinical sensitivity of a cytopathic effect assay.
    Massart C; Gibassier J; de Seze J; Debouverie M; Moreau T; Pelletier J; Vermersch P; Edan G
    Clin Chim Acta; 2008 May; 391(1-2):98-101. PubMed ID: 18249193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical impact of interferon beta antibodies in relapsing-remitting MS.
    Perini P; Calabrese M; Biasi G; Gallo P
    J Neurol; 2004 Mar; 251(3):305-9. PubMed ID: 15015010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
    Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency and magnitude of interferon β neutralizing antibodies in the evaluation of interferon β immunogenicity in patients with multiple sclerosis.
    Grossberg SE; Oger J; Grossberg LD; Gehchan A; Klein JP
    J Interferon Cytokine Res; 2011 Mar; 31(3):337-44. PubMed ID: 21226608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event.
    Kinkel RP; Kollman C; O'Connor P; Murray TJ; Simon J; Arnold D; Bakshi R; Weinstock-Gutman B; Brod S; Cooper J; Duquette P; Eggenberger E; Felton W; Fox R; Freedman M; Galetta S; Goodman A; Guarnaccia J; Hashimoto S; Horowitz S; Javerbaum J; Kasper L; Kaufman M; Kerson L; Mass M; Rammohan K; Reiss M; Rolak L; Rose J; Scott T; Selhorst J; Shin R; Smith C; Stuart W; Thurston S; Wall M;
    Neurology; 2006 Mar; 66(5):678-84. PubMed ID: 16436649
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose intravenous interferon beta in patients with neutralizing antibodies (HINABS): a pilot study.
    Millonig A; Rudzki D; Hölzl M; Ehling R; Gneiss C; Künz B; Berger T; Reindl M; Deisenhammer F
    Mult Scler; 2009 Aug; 15(8):977-83. PubMed ID: 19465447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?
    Sorensen PS; Koch-Henriksen N; Flachs EM; Bendtzen K
    Mult Scler; 2008 Jul; 14(6):837-42. PubMed ID: 18505772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS.
    Francis GS; Rice GP; Alsop JC;
    Neurology; 2005 Jul; 65(1):48-55. PubMed ID: 16009884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of neutralizing antibodies on the clinical efficacy of interferon beta in multiple sclerosis.
    Vartanian T; Sölberg Sørensen P; Rice G
    J Neurol; 2004 Jun; 251 Suppl 2():II25-30. PubMed ID: 15264109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of anti-IFN{beta} antibodies on MRI lesions of MS patients in the BECOME study.
    Pachner AR; Cadavid D; Wolansky L; Skurnick J
    Neurology; 2009 Nov; 73(18):1485-92. PubMed ID: 19884576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice.
    Jungedal R; Lundkvist M; Engdahl E; Ramanujam R; Westerlind H; Sominanda A; Hillert J; Fogdell-Hahn A
    Mult Scler; 2012 Dec; 18(12):1775-81. PubMed ID: 22551640
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis.
    Giovannoni G; Barbarash O; Casset-Semanaz F; Jaber A; King J; Metz L; Pardo G; Simsarian J; Sørensen PS; Stubinski B;
    Clin Ther; 2007 Jun; 29(6):1128-45. PubMed ID: 17692727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Appearance and disappearance of neutralizing antibodies during interferon-beta therapy.
    Sorensen PS; Koch-Henriksen N; Ross C; Clemmesen KM; Bendtzen K;
    Neurology; 2005 Jul; 65(1):33-9. PubMed ID: 15888603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity.
    Sominanda A; Rot U; Suoniemi M; Deisenhammer F; Hillert J; Fogdell-Hahn A
    Mult Scler; 2007 Mar; 13(2):208-14. PubMed ID: 17439886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
    Hegen H; Millonig A; Bertolotto A; Comabella M; Giovanonni G; Guger M; Hoelzl M; Khalil M; Killestein J; Lindberg R; Malucchi S; Mehling M; Montalban X; Polman CH; Rudzki D; Schautzer F; Sellebjerg F; Sørensen PS; Deisenhammer F
    Mult Scler; 2014 Apr; 20(5):577-87. PubMed ID: 24009164
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
    Kappos L; Freedman MS; Polman CH; Edan G; Hartung HP; Miller DH; Montalbán X; Barkhof F; Radü EW; Metzig C; Bauer L; Lanius V; Sandbrink R; Pohl C;
    Lancet Neurol; 2009 Nov; 8(11):987-97. PubMed ID: 19748319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.